|
Volumn 4, Issue 4, 2001, Pages 23-32
|
Clinical trials face heightened scrutiny as science and commerce appear to merge
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CLINICAL TRIAL;
COMMERCIAL PHENOMENA;
GENE THERAPY;
GOVERNMENT;
HEALTH CARE ORGANIZATION;
HUMAN;
HUMAN RIGHTS;
INFORMED CONSENT;
LAW SUIT;
MEDICAL RESEARCH;
MEDICARE;
PATIENT SELECTION;
POLICY;
REVIEW;
SCIENCE;
AGED;
ARTICLE;
BIOMEDICAL AND BEHAVIORAL RESEARCH;
CONFIDENTIALITY;
DRUG INDUSTRY;
ECONOMICS;
FOOD AND DRUG ADMINISTRATION;
FORGERY;
GOVERNMENT REGULATION;
HUMAN EXPERIMENT;
INFORMATION PROCESSING;
LEGAL APPROACH;
LEGAL ASPECT;
ORGANIZATION AND MANAGEMENT;
PROFESSIONAL STANDARD;
RESEARCH SUBJECT;
SAFETY;
STANDARD;
UNITED STATES;
NEW DRUG;
BIOMEDICAL AND BEHAVIORAL RESEARCH;
LEGAL APPROACH;
AGED;
CLINICAL TRIALS;
CONFIDENTIALITY;
DRUG INDUSTRY;
DRUGS, INVESTIGATIONAL;
ETHICS COMMITTEES, RESEARCH;
FRAUD;
GOVERNMENT REGULATION;
HUMAN EXPERIMENTATION;
HUMANS;
INFORMED CONSENT;
MEDICARE;
PATIENT SELECTION;
RECORDS;
RESEARCH SUBJECTS;
SAFETY;
UNITED STATES;
UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 0035686692
PISSN: 10955127
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (2)
|
References (10)
|